全文获取类型
收费全文 | 25750篇 |
免费 | 1307篇 |
国内免费 | 174篇 |
专业分类
耳鼻咽喉 | 197篇 |
儿科学 | 529篇 |
妇产科学 | 441篇 |
基础医学 | 2825篇 |
口腔科学 | 632篇 |
临床医学 | 2071篇 |
内科学 | 6764篇 |
皮肤病学 | 486篇 |
神经病学 | 2973篇 |
特种医学 | 778篇 |
外科学 | 3902篇 |
综合类 | 46篇 |
一般理论 | 5篇 |
预防医学 | 1076篇 |
眼科学 | 449篇 |
药学 | 1448篇 |
中国医学 | 31篇 |
肿瘤学 | 2578篇 |
出版年
2023年 | 163篇 |
2022年 | 334篇 |
2021年 | 749篇 |
2020年 | 444篇 |
2019年 | 620篇 |
2018年 | 696篇 |
2017年 | 554篇 |
2016年 | 620篇 |
2015年 | 691篇 |
2014年 | 1015篇 |
2013年 | 1273篇 |
2012年 | 2008篇 |
2011年 | 1999篇 |
2010年 | 1161篇 |
2009年 | 1076篇 |
2008年 | 1763篇 |
2007年 | 1815篇 |
2006年 | 1678篇 |
2005年 | 1649篇 |
2004年 | 1632篇 |
2003年 | 1356篇 |
2002年 | 1322篇 |
2001年 | 190篇 |
2000年 | 119篇 |
1999年 | 152篇 |
1998年 | 252篇 |
1997年 | 211篇 |
1996年 | 197篇 |
1995年 | 170篇 |
1994年 | 128篇 |
1993年 | 130篇 |
1992年 | 112篇 |
1991年 | 89篇 |
1990年 | 86篇 |
1989年 | 65篇 |
1988年 | 66篇 |
1987年 | 63篇 |
1986年 | 58篇 |
1985年 | 56篇 |
1984年 | 79篇 |
1983年 | 45篇 |
1982年 | 45篇 |
1981年 | 43篇 |
1980年 | 33篇 |
1979年 | 20篇 |
1978年 | 16篇 |
1977年 | 30篇 |
1976年 | 17篇 |
1974年 | 15篇 |
1973年 | 16篇 |
排序方式: 共有10000条查询结果,搜索用时 218 毫秒
991.
Moshe Phillip MD Chantal Mathieu MD Marcus Lind PhD Eiichi Araki MD Paolo di Bartolo MD Richard Bergenstal MD Simon Heller MD Lars Hansen MD Markus Florian Scheerer PhD Fredrik Thoren PhD Niki Arya MSc John Xu PhD Nayyar Iqbal MD Paresh Dandona MD DEPICT- DEPICT- Investigators 《Diabetes, obesity & metabolism》2021,23(2):549-560
992.
Giuseppe Tarantini MD Giulia Masiero MD Francesco Burzotta MD Vittorio Pazzanese MD Carlo Briguori MD Carlo Trani MD Tommaso Piva MD Federico De Marco MD Maurizio Di Biasi MD Paolo Pagnotta MD Marco Mojoli MD Gavino Casu MD Gennaro Giustino MD Giulia Lorenzoni PhD Matteo Montorfano MD Marco B. Ancona MD Federico Pappalardo MD Alaide Chieffo MD IMPella Mechanical Circulatory Support Device in Italy Registry authors 《Catheterization and cardiovascular interventions》2021,98(2):E222-E234
993.
Antonio Matteo Amadu Luigi Angelo Vaira Jerome R. Lechien Mariano Scaglione Luca Saba Maria Luisa Lampus Stefano Giorgio Profili Serge-Daniel Le Bon Giovanni Salzano Fabio Maglitto Sven Saussez Paolo Boscolo-Rizzo Claire Hopkins Giacomo De Riu 《International forum of allergy & rhinology》2022,12(1):103-107
994.
Fernando Rizzello Carlo Calabrese Marco Salice Lucia Calandrini Hana Privitera Laura Melotti Giulia Peruzzi Nikolas Dussias Andrea Belluzzi Eleonora Scaioli Anastasio Decorato Antonio Siniscalchi Eleonora Filippone Silvio Laureti Matteo Rottoli Gilberto Poggioli Paolo Gionchetti 《Digestive and liver disease》2021,53(3):271-276
BackgroundItaly has been one of the most affected countries in the world by COVID-19. There has been increasing concern regarding the impact of COVID‐19 on patients with inflammatory bowel disease (IBD), particularly in patients treated with immunosuppressants or biologics. The aim of our study is to understand the incidence of COVID-19 in a large cohort of patients with IBD. Furthermore, we analyzed possible risk factors for infection and severity of COVID-19.MethodsThis was an observational study evaluating the impact of COVID-19 on IBD patients in a single tertiary center. A 23 multiple-choice-question anonymous survey was administered to 1200 patients with IBD between March 10th and June 10th 2020.Results1158 questionnaires were analyzed. The majority of patients had Crohn's disease (CD) (60%) and most of them were in clinical remission. Among the 26 patients (2.2%) who tested positive for COVID-19, only 5 (3CD) were on biological treatment and none required hospitalization. Two patients died and were on treatment with mesalazine only. Of the 1158 patients, 521 were on biological therapy, which was discontinued in 85 (16.3%) and delayed in 195 patients (37.4%). A worsening of IBD symptoms was observed in 200 patients on biological therapy (38.4%). Most of these patients, 189 (94.5%), had stopped or delayed biological treatment, while 11 (5.5%) had continued their therapy regularly (p<0.001).ConclusionsOur data are in line with the current literature and confirm a higher incidence compared to the general population. Biological therapy for IBD seems to not be a risk factor for infection and should not be discontinued in order to avoid IBD relapse. 相似文献
995.
Giulia Stornelli Antonio Faba Andrea Di Schino Paolo Folgarait Maria Rita Ridolfi Ermanno Cardelli Roberto Montanari 《Materials》2021,14(6)
In this paper, the best laser powder bed fusion (L-PBF) printing conditions for FeSi steels with two different Si content (3.0% and 6.5%) are defined. Results show very strict processing window parameters, following a lack of fusion porosity at low specific energy values and keyhole porosity in correspondence with high specific energy values. The obtained microstructure consists of grains with epitaxial growth starting from the grains already solidified in the underling layer. This allows the continuous growth of the columnar grains, directed parallel to the built direction of the component. The magnetic behaviour of FeSi6.5 samples, although the performances found do not still fully reach those of the best commercial electrical steels (used to manufacture magnetic cores of electrical machines and other similar magnetic components), appears to be quite promising. An improvement of the printing process to obtain thin sheets with increased Si content, less than 0.5 mm thick, with accurate geometry and robust structures, can result to an interesting technology for specific application where complex geometries and sophisticated shapes are required, avoiding mechanical machining processes for electrical steel with high silicon content. 相似文献
996.
997.
Fabrizio Drago Irma Battipaglia Pietro Paolo Tamborrino Luigina Porco Camilla Calvieri Mario Salvatore Russo Vincenzo Pazzano Romolo Remoli Massimo Stefano Silvetti 《Congenital heart disease》2021,16(6):561-572
Background: Cryoablation of accessory pathways (APs) is effective and very safe in children, as previously
reported by our group. The aim of this retrospective study was to evaluate the current efficacy of 3D non-fluoroscopic cryoablation of right sided APs in children, comparing results obtained with the Ensite VelocityTM and the
more recent Ensite PrecisionTM 3D mapping systems. Methods and Results: From January 2016 to December
2019, 102 pediatric patients [mean age 12.5 ± 2.8, 62 males (61% of total cohort)] with right APs underwent
3D non-fluoroscopic transcatheter cryoablation at our Institution. Fifteen (14.7%) patients had previously undergone catheter ablation. Acute procedural success rate was 95.1% (n = 97). No significant differences were detected
in acute success rates achieved with Ensite VelocityTM or Ensite PrecisionTM systems nor between manifest (94%)
and concealed APs (100%). No permanent complications occurred. During follow-up (428 ± 286 days, median
396 days [interquartile range 179-713]), 19 patients (19.6%) had recurrences. Recurrences were more frequent
for parahissian/anterior APs compared to midseptal/posterior and lateral APs (p = 0.043). Recurrences were
not related to the Ensite system used. A redo ablation procedure was attempted in 13 cases, 11 cryoablation
and 2 radiofrequency ablations: the former was successful in 10 cases out of 11 (90.9%). Conclusion: 3D cryoablation of right-sided APs is associated with a very high acute success rate with limited use of fluoroscopy,
resulting in great benefit to the children. Recurrence rates are not high and patients can be retreated with
cryo-energy with higher success rates. 相似文献
998.
999.
Paolo Tarantino 《Expert opinion on biological therapy》2019,19(5):383-385
In phase III ImPassion130 trial, the addition of immunotherapy to chemotherapy improved overall survival in metastatic triple-negative breast cancer patients. This benefit was significant only in patients harboring PD-L1-positive tumors, suggesting that stratification according to response biomarkers is needed to achieve consistent responses. Besides PD-L1 expression, a variety of potential biomarkers are under investigation for predicting immunotherapy efficacy in breast cancer, such as tumor-infiltrating lymphocytes, gene signatures, tumor mutational burden, microsatellite instability, and gut microbiome. Enriching future trials through these biomarkers could help identifying the population of responders, realizing what has been called precision immunotherapy. 相似文献
1000.
Prandoni P 《Blood》2005,106(13):4027-4033
Venous thromboembolism (VTE) is a frequent complication in cancer patients and represents an important cause of morbidity and mortality. Especially in patients who have a poor life expectancy, preventing death from pulmonary embolism is the mainstay of treatment. Critically ill patients should promptly be administered thrombolytic drugs. Except for selected patients requiring aggressive therapy, the initial VTE treatment should be conducted with either adjusted-dose unfractionated heparin or fixed-dose low-molecular-weight heparin (LMWH). LMWHs have the potential to greatly simplify the initial treatment of VTE, making the treatment of suitable patients feasible in an outpatient setting. During anticoagulant therapy, cancer patients have a 2- to 4-fold higher risk of recurrent VTE and major bleeding complications when compared with noncancer patients. The long-term administration of LMWH should be considered as an alternative to anti-vitamin K drugs in patients with advanced disease and in those with conditions limiting the use of oral anticoagulants. Prolongation of anticoagulation should be considered for as long as the malignant disorder is active. The evidence of lowered cancer mortality in patients on LMWH has stimulated renewed interest in these agents as antineoplastic drugs and raises the distinct possibility that cancer and thrombosis share common mechanisms. 相似文献